<DOC>
	<DOC>NCT00625950</DOC>
	<brief_summary>Dopamine agonists, such as quinagolide, are able to act on the VEGFR-2 blocking antibodies, diminishing Vascular Endothelial Growth Factor effect on angiogenesis in human endometriotic lesions.</brief_summary>
	<brief_title>Endometriosis Patients Undergoing Quinagolide Treatment</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Hyperprolactinemia</mesh_term>
	<criteria>Hyperprolactinemia Unexplained infertility Endometriosis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>37 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Hyperprolactinemia</keyword>
	<keyword>Endometriosis</keyword>
	<keyword>laparoscopy</keyword>
	<keyword>angiogenesis, VEGF</keyword>
</DOC>